Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
6.759T
Market Weight
9.88%
Industries
11
Companies
1202
Healthcare S&P 500 ^GSPC
Loading Chart for Healthcare
DELL

Day Return

Sector
0.03%
S&P 500
0.00%

YTD Return

Sector
6.77%
S&P 500
26.77%

1-Year Return

Sector
12.28%
S&P 500
31.61%

3-Year Return

Sector
5.11%
S&P 500
32.11%

5-Year Return

Sector
53.08%
S&P 500
95.49%

Note: Sector performance is calculated based on the previous closing price of all sector constituents

Industries in This Sector

Select an Industry for a Visual Breakdown

IndustryMarket WeightYTD Return
All Industries
100.00%
6.77%
Drug Manufacturers - General
33.22%
9.86%
Healthcare Plans
13.56%
0.90%
Medical Devices
12.66%
6.38%
Biotechnology
11.35%
-1.26%
Diagnostics & Research
10.76%
0.57%
Medical Instruments & Supplies
7.77%
25.28%
Medical Care Facilities
2.94%
15.77%
Drug Manufacturers - Specialty & Generic
2.83%
0.79%
Medical Distribution
2.52%
20.11%
Health Information Services
2.27%
19.47%
Pharmaceutical Retailers
0.12%
-63.91%

Note: Percentage % data on heatmap indicates Day Return

Largest Companies in This Sector

View More
Table View
Heatmap View
Name
Last Price
1Y Target Est.
Market Weight
Market Cap
Day Change %
YTD Return
Avg. Analyst Rating
813.77 999.43 10.98% 731.841B +1.75% +39.60%
Buy
608.60 625.10 8.40% 560.085B +0.01% +15.60%
Buy
153.50 175.98 5.56% 370.512B -0.84% -2.06%
Buy
182.43 208.90 4.84% 322.639B +0.36% +17.72%
Buy
102.14 133.43 3.93% 262.152B +1.53% -6.31%
Buy
532.10 657.43 3.05% 203.528B +0.41% +0.25%
Buy
116.52 130.24 3.04% 202.405B -0.25% +5.86%
Buy
536.68 539.24 2.87% 191.153B -1.14% +59.08%
Buy
240.66 288.34 2.61% 173.826B -0.26% +4.03%
Buy
281.06 335.10 2.27% 151.076B +1.06% -2.42%
Buy

Investing in the Healthcare Sector

Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds

ETF Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
147.30 39.816B 0.09% +8.01%
271.68 20.549B 0.10% +8.37%
98.36 7.244B 0.35% +10.16%
140.85 7.086B 0.45% +3.68%
60.61 4.783B 0.40% +12.30%

Mutual Fund Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
214.52 45.697B 0.30% +2.59%
90.48 45.697B 0.30% +2.62%
135.91 20.549B 0.10% +8.36%
92.74 15.399B 0.80% +5.24%
97.11 14.589B 0.80% +10.20%

Healthcare Research

View More

Discover the Latest Analyst and Technical Research for This Sector

  • Daily – Vickers Top Insider Picks for 12/03/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Buyers & Sellers for 12/03/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Analyst Report: BioNTech SE

    BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

    Rating
    Price Target
     
  • Analyst Report: Moderna, Inc.

    Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

    Rating
    Price Target
     

From the Community

Healthcare News